Reimagining Antimicrobial Drug Delivery: Spatiotemporally Adaptive Therapeutics for Biofilm-Associated Infections and Antimicrobial Resistance.
- 1Department of Public Health, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah 51452, Saudi Arabia.
Abstract
Antimicrobial therapy may fail even when an agent is intrinsically active if effective drug exposure is not achieved at the site of infection at the appropriate time. This challenge is particularly important in biofilm-associated infections and infections caused by drug-resistant pathogens, where biological barriers, spatial heterogeneity, and changing microbial states can limit treatment effectiveness. This narrative review examines advanced antimicrobial delivery from a problem-oriented perspective, focusing on the therapeutic challenges that delivery systems are designed to address. It explores how antimicrobial exposure can be aligned with the location, biological state, and changing course of infection. The review examines the biological and pharmacological barriers that restrict antimicrobial activity and discusses strategies designed to improve drug access, retention, release, and local activity. Localized delivery, responsive and externally triggered systems, controlled and sequential delivery, and multimodal therapy are considered as implementation strategies within a common spatiotemporal framework. Particular attention is given to the relationship between formulation design, local drug exposure, biological response, and therapeutic outcome. The review further examines the factors that determine whether a technically promising system has a realistic clinical role, including safety, reproducibility, manufacturability, model relevance, and demonstrable benefits over simpler approaches. Future priorities are considered from a clinically defined perspective. Overall, the review argues that the value of advanced antimicrobial delivery lies not in carrier complexity alone, but in its capacity to provide a measurable and reproducible therapeutic advantage for a clearly defined infection setting.
Related
- Bloodstream Infections in Patients with Malignancy: Microbiological Epidemiology, Antimicrobial Resistance, and Factors Associated with Mortality in a Nine-Year Single-Center Retrospective Cohort
- Epidemiology, microbiological characteristics, and antimicrobial resistance of device-associated healthcare-associated infections in a neonatal intensive care unit: a six-year surveillance study
- Formulation, physicochemical characterization, and antimicrobial evaluation of drug-loaded essential oil microemulsions against Methicillin-resistant Staphylococcus aureus -associated diabetic foot ulcer infections
- Extending prophylactic antimicrobial use beyond 48 h postoperatively fails to reduce surgical site infections and other healthcare-associated infections in patients undergoing colorectal resection: a Propensity Score Matching study
- Clostridioides difficile infections and beyond: molecular epidemiology, One Health transmission chains, under-surveilled regions, and the next generation of diagnostics, therapeutics, and vaccines
BibTeX
@article{marzouk2026reimagining,
title = {{Reimagining Antimicrobial Drug Delivery: Spatiotemporally Adaptive Therapeutics for Biofilm-Associated Infections and Antimicrobial Resistance.}},
author = {Eman Marzouk and Mahmoud Jaber},
journal = {Pharmaceutics},
year = {2026},
month = sep,
doi = {10.3390/pharmaceutics18101202},
url = {https://europepmc.org/article/MED/42942734},
note = {CC BY},
}
RIS
TY - JOUR
TI - Reimagining Antimicrobial Drug Delivery: Spatiotemporally Adaptive Therapeutics for Biofilm-Associated Infections and Antimicrobial Resistance.
AU - Eman Marzouk
AU - Mahmoud Jaber
PY - 2026
DA - 2026/09/22
JO - Pharmaceutics
DO - 10.3390/pharmaceutics18101202
UR - https://europepmc.org/article/MED/42942734
AB - Antimicrobial therapy may fail even when an agent is intrinsically active if effective drug exposure is not achieved at the site of infection at the appropriate time. This challenge is particularly important in biofilm-associated infections and infections caused by drug-resistant pathogens, where biological barriers, spatial heterogeneity, and changing microbial states can limit treatment effectiveness. This narrative review examines advanced antimicrobial delivery from a problem-oriented perspective, focusing on the therapeutic challenges that delivery systems are designed to address. It explores how antimicrobial exposure can be aligned with the location, biological state, and changing course of infection. The review examines the biological and pharmacological barriers that restrict antimicrobial activity and discusses strategies designed to improve drug access, retention, release, and local activity. Localized delivery, responsive and externally triggered systems, controlled and sequential delivery, and multimodal therapy are considered as implementation strategies within a common spatiotemporal framework. Particular attention is given to the relationship between formulation design, local drug exposure, biological response, and therapeutic outcome. The review further examines the factors that determine whether a technically promising system has a realistic clinical role, including safety, reproducibility, manufacturability, model relevance, and demonstrable benefits over simpler approaches. Future priorities are considered from a clinically defined perspective. Overall, the review argues that the value of advanced antimicrobial delivery lies not in carrier complexity alone, but in its capacity to provide a measurable and reproducible therapeutic advantage for a clearly defined infection setting.
SN - 1999-4923
ER -